Cortical Atrophy is Relevant in Multiple Sclerosis at Clinical Onset

Overview

Journal J Neurol

Specialty Neurology

Date 2007 Mar 16

PMID 17361339

Citations 101

Authors

Massimiliano Calabrese

Matteo Atzori

Valentina Bernardi

Aldo Morra

Chiara Romualdi

Luciano Rinaldi

Matthew J M McAuliffe

Luigi Barachino

Paola Perini

Bruce Fischl

Leontino Battistin

Paolo Gallo

Affiliations

Soon will be listed here.

Abstract

Introduction: Increasing evidence suggests relevant cortical gray matter pathology in patients with Multiple Sclerosis (MS), but how early this pathology begins; its impact on clinical disability and which cortical areas are primarily affected needs to be further elucidated.

Methods: 115 consecutive patients (10 Clinically Isolated Syndrome (CIS), 32 possible MS (p-MS), 42 Relapsing Remitting MS (RR-MS), 31 Secondary Progressive MS (SP-MS)), and 40 age/gender-matched healthy volunteers (HV) underwent a neurological examination and a 1.5 T MRI. Global and regional Cortical Thickness (CTh) measurements, brain parenchyma fraction and T2 lesion load were analyzed.

Results: We found a significant global cortical thinning in p-MS (2.22 +/- 0.09 mm), RR-MS (2.16 +/- 0.10 mm) and SP-MS (1.98 +/- 0.11 mm) compared to CIS (2.51 +/- 0.11 mm) and HV (2.48 +/- 0.08 mm). The correlations between mean CTh and white matter (WM) lesion load was only moderate in MS (r = -0.393, p = 0.03) and absent in p-MS (r = -0.147, p = 0.422). Analysis of regional CTh revealed that the majority of cortical areas were involved not only in MS, but also in p-MS. The type of clinical picture at onset (in particular, pyramidal signs/symptoms and optic neuritis) correlated with atrophy in the corresponding cortical areas.

Discussion: Cortical thinning is a diffuse and early phenomenon in MS already detectable at clinical onset. It correlates with clinical disability and is partially independent from WM inflammatory pathology.

Citing Articles

Immunoglobulin G and Complement as Major Players in the Neurodegeneration of Multiple Sclerosis.

Kennedy P, Fultz M, Phares J, Yu X Biomolecules. 2024; 14(10).

PMID: 39456143 PMC: 11506455. DOI: 10.3390/biom14101210.

Real-world analysis of brain atrophy in multiple sclerosis patients with an artificial intelligence based software tool.

Reinhardt C, Angstwurm K, Freudenstein D, Lee D, Wendl C, Linker R Neurol Res Pract. 2024; 6(1):40.

PMID: 39113151 PMC: 11308334. DOI: 10.1186/s42466-024-00339-y.

A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis.

Barnett M, Wang D, Beadnall H, Bischof A, Brunacci D, Butzkueven H NPJ Digit Med. 2023; 6(1):196.

PMID: 37857813 PMC: 10587188. DOI: 10.1038/s41746-023-00940-6.

Exploring the impact of ketogenic diet on multiple sclerosis: obesity, anxiety, depression, and the glutamate system.

de la Rubia Orti J, Cuerda-Ballester M, Sanchis-Sanchis C, Lajara Romance J, Navarro-Illana E, Garcia Pardo M Front Nutr. 2023; 10:1227431.

PMID: 37693246 PMC: 10485376. DOI: 10.3389/fnut.2023.1227431.

Links between Neuroanatomy and Neurophysiology with Turning Performance in People with Multiple Sclerosis.

Swanson C, Fling B Sensors (Basel). 2023; 23(17).

PMID: 37688084 PMC: 10490793. DOI: 10.3390/s23177629.

References

Dalton C, Chard D, Davies G, Miszkiel K, Altmann D, Fernando K . Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain. 2004; 127(Pt 5):1101-7. DOI: 10.1093/brain/awh126. View

BROWNELL B, Hughes J . The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962; 25:315-20. PMC: 495470. DOI: 10.1136/jnnp.25.4.315. View

Pozzilli C, Romano S, Cannoni S . Epidemiology and current treatment of multiple sclerosis in Europe today. J Rehabil Res Dev. 2002; 39(2):175-85. View

Pagani E, Rocca M, Gallo A, Rovaris M, Martinelli V, Comi G . Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. AJNR Am J Neuroradiol. 2005; 26(2):341-6. PMC: 7974082. View

De Stefano N, Matthews P, Filippi M, Agosta F, De Luca M, Bartolozzi M . Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology. 2003; 60(7):1157-62. DOI: 10.1212/01.wnl.0000055926.69643.03. View

McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1):121-7. DOI: 10.1002/ana.1032. View

Tiberio M, Chard D, Altmann D, Davies G, Griffin C, Rashid W . Gray and white matter volume changes in early RRMS: a 2-year longitudinal study. Neurology. 2005; 64(6):1001-7. DOI: 10.1212/01.WNL.0000154526.22878.30. View

Fischl B, Sereno M, Dale A . Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage. 1999; 9(2):195-207. DOI: 10.1006/nimg.1998.0396. View

Chard D, Griffin C, McLean M, Kapeller P, Kapoor R, Thompson A . Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain. 2002; 125(Pt 10):2342-52. DOI: 10.1093/brain/awf240. View

10.

Geurts J, Bo L, Pouwels P, Castelijns J, Polman C, Barkhof F . Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol. 2005; 26(3):572-7. PMC: 7976495. View

11.

Peterson J, Bo L, Mork S, Chang A, Trapp B . Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol. 2001; 50(3):389-400. DOI: 10.1002/ana.1123. View

12.

Rudick R, Fisher E, Lee J, Simon J, Jacobs L . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology. 1999; 53(8):1698-704. DOI: 10.1212/wnl.53.8.1698. View

13.

Patwardhan M, Matchar D, Samsa G, McCrory D, Williams R, Li T . Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005; 11(2):232-9. DOI: 10.1191/1352458505ms1137oa. View

14.

Fischl B, Liu A, Dale A . Automated manifold surgery: constructing geometrically accurate and topologically correct models of the human cerebral cortex. IEEE Trans Med Imaging. 2001; 20(1):70-80. DOI: 10.1109/42.906426. View

15.

Pelletier D, Garrison K, Henry R . Measurement of whole-brain atrophy in multiple sclerosis. J Neuroimaging. 2004; 14(3 Suppl):11S-19S. DOI: 10.1177/1051228404266264. View

16.

Sailer M, Fischl B, Salat D, Tempelmann C, Schonfeld M, Busa E . Focal thinning of the cerebral cortex in multiple sclerosis. Brain. 2003; 126(Pt 8):1734-44. DOI: 10.1093/brain/awg175. View

17.

Polman C, Reingold S, Edan G, Filippi M, Hartung H, Kappos L . Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. DOI: 10.1002/ana.20703. View

18.

Chard D, Griffin C, Rashid W, Davies G, Altmann D, Kapoor R . Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis. Mult Scler. 2004; 10(4):387-91. DOI: 10.1191/1352458504ms1050oa. View

19.

Tintore M, Rovira A, Rio J, Nos C, Grive E, Sastre-Garriga J . New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology. 2003; 60(1):27-30. DOI: 10.1212/wnl.60.1.27. View

20.

Amato M, Bartolozzi M, Zipoli V, Portaccio E, Mortilla M, Guidi L . Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology. 2004; 63(1):89-93. DOI: 10.1212/01.wnl.0000129544.79539.d5. View